Predictive genomics is the culmination of the Human Genome Project meeting precision health. Predictive genomics helps identify disease risks with polygenic risk scores (PRSs) and manage adverse drug responses (ADRs) with pharmacogenomics (PGx). The understanding of PRS and PGx will significantly change personalized and population health management in the future. In this series of three webinars the speakers will illustrate how predictive genomics allows for the prediction of many common disease risks and drug response, in turn helping to improve outcomes and optimize costs.
In the first of the three-part webinar series Dr. Aarno Palotie of the Institute for Molecular Medicine Finland (FIMM), the University of Helsinki, and the Broad Institute of MIT and Harvard will share the emerging vision of preemptive health care enabled by genomics, expanding on the value of PRS and PGx in disease risk stratification and medication management, with examples from his group’s work.
Institute for Molecular Medicine Finland (FIMM)
Also, Dr. Andres Metspalu of the Estonian Genome Center at the University of Tartu, the Institute of Genomics, and the Estonian biobank will speak about the future of preemptive health care, highlighting why population-based biobanks are important for building a predictive genomics program, and showcasing examples from his work with a number of major European initiatives.
Estonian Genome Center, University of Tartu
The second webcast of the three-part series will have Prof. Samuli Ripatti of the Institute for Molecular Medicine Finland (FIMM) and The Broad Institute of MIT and Harvard discuss essentials of building a predictive genomics program, with examples of cardiometabolic diseases and common cancers.
Institute for Molecular Medicine Finland (FIMM) and The Broad Institute of MIT and Harvard
The final webcast in this predictive genomics webinar series will feature Dr. Pui-Yan Kwok of the University of California, San Francisco, and Academia Sinica, Taipei, Taiwan and will highlight how the Applied Biosystems Axiom platform has allowed for early results from >250,000 participants part of their Taiwan Precision Medicine Initiative. The results discussed during the webcast illustrate that with a large number of tested and affected, population-scale genetic testing can be used to identify high risk individuals and improve their health management through early disease screening and optimizing medication use.
University of California, San Francisco and Academia Sinica, Taipei, Taiwan